Plain-English translation of NCT06980584 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether rituximab lymph node injection combined with a lung vessel procedure works better than the procedure alone for treating a condition called fibrosing mediastinitis that causes high lung pressure. Fibrosing mediastinitis happens when scar tissue builds up in the center of your chest and squeezes your lung blood vessels, making it hard to breathe. The study compares two groups: one receives both the procedure and the medication, and one receives just the procedure.
High lung pressure from chest scarring is hard to treat and can seriously limit what patients can do. Doctors want to know if adding this medication to the standard procedure might help more patients feel better and breathe easier.
You likely qualify if…
You likely don't qualify if…
If you join, you'll be randomly assigned to receive either the procedure plus the medication, or just the procedure. Both groups will need to visit the hospital for the procedures and then return for follow-up visits at 3, 6, and 12 months after treatment. During these visits, doctors will check your symptoms, run breathing and heart tests, and take imaging scans to see how well the treatment is working.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
China